Conv. Plasma
Nigella Sativa

All famotidine studies
Meta analysis
study COVID-19 treatment researchFamotidineFamotidine (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Famotidine in COVID-19 treatment

Taşdemir et al., Konuralp Tıp Dergisi, doi:10.18521/ktd.935888
Jul 2021  
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality 45% Improvement Relative Risk ICU admission 37% Hospitalization time 18% Recovery time 20% Famotidine  Taşdemir et al.  LATE TREATMENT Is late treatment with famotidine beneficial for COVID-19? Retrospective 179 patients in Turkey Study compares with pantoprazole, results vs. placebo may differ Shorter hospitalization (p=0.003) and faster recovery (p=0.04) Taşdemir et al., Konuralp Tıp Dergisi, Jul 2021 Favorsfamotidine Favorspantoprazole 0 0.5 1 1.5 2+
Famotidine for COVID-19
25th treatment shown to reduce risk in October 2021
*, now with p = 0.00026 from 30 studies, recognized in 2 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,300+ studies for 75 treatments.
Retrospective 179 hospitalized patients in Turkey, 85 treated with famotidine and 94 treated with pantoprazole, showing faster recovery with famotidine in unadjusted results.
This study is excluded in the after exclusion results of meta analysis: excessive unadjusted differences between groups.
risk of death, 44.7% lower, RR 0.55, p = 0.29, treatment 5 of 85 (5.9%), control 10 of 94 (10.6%), NNT 21.
risk of ICU admission, 36.8% lower, RR 0.63, p = 0.36, treatment 8 of 85 (9.4%), control 14 of 94 (14.9%), NNT 18.
hospitalization time, 18.1% lower, relative time 0.82, p = 0.003, treatment 85, control 94.
recovery time, 20.0% lower, relative time 0.80, p = 0.04, treatment 85, control 94, duration of fever.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Taşdemir et al., 12 Jul 2021, retrospective, Turkey, peer-reviewed, 7 authors, this trial compares with another treatment - results may be better when compared to placebo.
This PaperFamotidineAll
Famotidine in COVID-19 treatment
Canatan Taşdemir, Ertuğrul Güçlü, Zeynep Devran Muharremoğlu, El Medina Hotschka, Yusuf Aydemir, Aziz Öğütlü, Oğuz Karabay
Konuralp Tıp Dergisi, doi:10.18521/ktd.935888
Objective: Famotidine is an H2 receptor antagonist (H2RA) and has been shown to have antiviral properties in in vitro studies. Pantoprazole is one of the proton pump inhibitors (PPI). In this study, it was aimed to compare the efficacy of famotidine with pantoprazole in the treatment of COVID-19. Methods: Patients who were hospitalized and given famotidine and pantoprazole treatment for at least 48 hours were included in the study. Demographic, clinical and laboratory findings of the patients were analyzed retroprospectively from the patient files. The patients were divided into two groups as the famotidine group and the pantoprazole group. The groups were compared in terms of the need for intensive care and mortality rates. In addition, among the groups, the number of patients with normal oxygen saturation at discharge, number of days needed for oxygen support, number of days with fever, and length of hospital stay were evaluated. Results: A total of 179 Covid-19 patients (85 famotidine, 94 pantoprazole) were included in the study. Demographic findings and other symptoms except dyspnea were similar in both groups. Dyspnea, chronic diseases, and the number of patients given steroids were higher in those who were given pantoprazole (p<0.05). Mortality and ICU need were similar in both groups (respectively; p=0.25, p=0.26). The number of days with fever, duration of hospitalization, and the number of days requiring oxygen support were less in those given famotidine (respectively; p=0.04, p=0.003, p=0.014). Conclusions: Famotidine did not reduce the need for intensive care and mortality in COVID-19 patients treated in the hospital. New therapeutic agents are needed to reduce disease severity and mortality.
Bourinbaiar, Fruhstorfer, The effect of histamine type 2 receptor antagonists on human immunodeficiency virus (HIV) replication: identification of a new class of antiviral agents, Life Sci
Branco, Yoshikawa, Pietrobon, Sato, Role of Histamine in Modulating the Immune Response and Inflammation, Mediators Inflamm
Ennis, Tiligada, Histamine receptors and COVID-19, Inflammation Research
Fajgenbaum, June, Cytokine Storm, N Engl J Med, doi:10.1056/NEJMra2026131
Freedberg, Conigliaro, Wang, Tracey, Callahan et al., Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study, Gastroenterology, doi:10.1053/j.gastro.2020.05.053
García, Immune response, inflammation, and the clinical spectrum of COVID-19, Frontiers in immunology
Kalpaklıoglu, Kalkan, Kavut, Histamin ve antihistaminler. Türkiye Klinikleri İmmünoloji Allerji-Özel Konular
Li, Xu, Yu, Wang, Tao et al., Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan, J Allergy Clin Immunol, doi:10.1016/j.jaci.2020.04.006
Loffredo, Lucero, Chen, Connell, Bergqvist et al., The effect of famotidine on SARS-Cov-2 proteases and virus replication, doi:10.1101/2020.07.15.203059v1.full.pdf
Trivedi, Verma, Kumar, Possible treatment and strategies for COVID-19: review and assessment, Eur Rev Med Pharmacol Sci
{ 'indexed': { 'date-parts': [[2021, 12, 17]], 'date-time': '2021-12-17T13:27:07Z', 'timestamp': 1639747627637}, 'reference-count': 12, 'publisher': 'Konuralp Medical Journal', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'short-container-title': [], 'DOI': '10.18521/ktd.935888', 'type': 'journal-article', 'created': {'date-parts': [[2021, 7, 13]], 'date-time': '2021-07-13T06:21:08Z', 'timestamp': 1626157268000}, 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': ['Famotidine in COVID-19 treatment'], 'prefix': '10.18521', 'author': [ {'given': 'Canatan', 'family': 'TAŞDEMİR', 'sequence': 'first', 'affiliation': []}, {'given': 'Ertuğrul', 'family': 'GÜÇLÜ', 'sequence': 'additional', 'affiliation': []}, { 'given': 'Zeynep', 'family': 'DEVRAN MUHARREMOĞLU', 'sequence': 'additional', 'affiliation': []}, {'given': 'El Medina', 'family': 'HOTSCHKA', 'sequence': 'additional', 'affiliation': []}, {'given': 'Yusuf', 'family': 'AYDEMİR', 'sequence': 'additional', 'affiliation': []}, {'given': 'Aziz', 'family': 'ÖĞÜTLÜ', 'sequence': 'additional', 'affiliation': []}, {'given': 'Oğuz', 'family': 'KARABAY', 'sequence': 'additional', 'affiliation': []}], 'member': '7783', 'published-online': {'date-parts': [[2021, 7, 12]]}, 'container-title': ['Konuralp Tıp Dergisi'], 'original-title': [], 'deposited': { 'date-parts': [[2021, 7, 13]], 'date-time': '2021-07-13T06:21:26Z', 'timestamp': 1626157286000}, 'score': 1, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 7, 12]]}, 'references-count': 12, 'URL': '', 'relation': {}, 'ISSN': ['1309-3878'], 'issn-type': [{'value': '1309-3878', 'type': 'print'}], 'subject': ['General Medicine'], 'published': {'date-parts': [[2021, 7, 12]]}}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop